Arizona State Retirement System lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.8% in the ...

Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S.

The BioWorld Neurological Diseases Index closed 2024 down 20.27%, extending its decline from -13.4% at the end of November. After falling to -12.2% in April, the index briefly rebounded, narrowing ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...

Meeting to be held in New York on March 6 hosted by Piper Sandler.Discover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

The global PFAS Testing Market, valued at US$379.2 million in 2023, is forecasted to grow at a robust CAGR of 14.5%, reaching US$429.2 million in 2024 and an impressive US$969.5 million by 2030. The ...